PubMed Health⌕ Search

Biomedical subjects

S Levander

Publications and source records attributed to S Levander.

At least 37 records · Page 2Linked to original sources
PubMed1999

Dyslexia among Swedish prison inmates in relation to neuropsychology and personality.

Several investigations have reported high frequencies of reading and writing disabilities in criminal populations. The aims of the present study were to assess the frequency of dyslexia among Swedish prison inmates and to relate dyslexia to other indices of neuropsychological functions. Sixty-three prison inmates with Swedish as their native language, age 19 to 57 years, were examined by interviews, tests of academic achievement, and neuropsychological assessment. Twenty-six (41%) were diagnosed as dyslexic. As expected, the dyslexic group performed more poorly on verbal tests as compared to the normal readers among the prison inmates, but they also performed more poorly on tests measuring nonverbal abilities. The dyslexic group had higher frequencies of paranoid and avoidant personality disorders compared to the nondyslexics. They also reported higher levels of anxiety and suspicion and a lower degree of socialization. Previous studies report low IQ to be associated with criminal propensity, supporting the interpretation that a double handicap (dyslexia and low IQ) increases the risk of entering a criminal career and remaining in it.

Adult↗
PubMed1998

[Hyperactivity syndrome is common among prisoners. ADHD not only a pediatric psychiatric diagnosis].

Although ADHD (attention deficit hyperactivity disorder) is one of the most common psychiatric disorders in children, much less is known about its prevalence among adults (where the clinical picture may vary), and it is almost never diagnosed in adult psychiatry. The article consists in a report showing the disorder to have been a common finding in a group of prison inmates, and to have been characterised by strong relationships with a series of other psychiatric disorders (e.g. anxiety and personality disorders) with the presence of self-reported anomalous alcohol reactions, and with the degree of criminality. Current diagnostic practice is unfortunate, partly due to the risk of overdiagnosis of anxiety and personality disorders, and partly due to the risk of missing a condition possibly amenable to treatment.

Adult↗
PubMed1998

Dopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: a pilot study.

Astra (S)-3-[123I]iodo-5,6-dimethoxyl-N-[(1-ethyl-2-pyrrolidinyl)methyl] -salicylamide (123I-NCQ298) is a new high-affinity D2-receptor ligand for use in single photon emission tomography (SPET) studies. We have studied the biodistribution and absorbed radiation dose of 123I-NCQ298 in humans. The mean effective dose for adults was 0.055 mSv MBq(-1). Brain uptake and clearance was measured with a head dedicated SPET camera. 123I-NCQ298 showed specific uptake in the basal ganglia with a low clearance rate (time constant of 9-34 h). The extrastriatal binding was variable (average 30%, maximum 60% of that in the basal ganglia at 1 h), but with a clearance rate twice that of the basal ganglia. The fairly high level of extrastriatal binding precluded the use of a quotient between the basal ganglia and cerebellum-to-frontal cortex 123I-NCQ298 concentration as a measure for basal ganglia D2-receptor density. Chronic schizophrenic patients treated with conventional neuroleptics had a decreased affinity for 123I-NCQ298 in the basal ganglia in the range 10-60% of the median value for the control, untreated subjects.

Adult↗
PubMed1997

Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.

A total of 51 chronic psychotic out-patients, with a median age of 51 years and median duration of psychosis of 23 years, treated with depot neuroleptics, entered a 5-year follow-up study with assessments of symptoms, side-effects and plasma concentration of the depot drug (follow-up (FU) patients). The outcome for 38 non-eligible (NE) patients was obtained from hospital case reports. The relapse rate was higher for NE than for FU patients (71% vs. 50%). The mortality rate was 9%, and the median age at death was 47 years. Half of the FU patients completed 3 years of treatment uneventfully. Of the total of 89 patients, only 18% remained stable over a period of 5 years. The depot dose was approximately the same after 3 years (median 255 mg, range 50-1018 mg chlorpromazine equivalents).

Adult↗
PubMed1996

Large variations of plasma levels during maintenance treatment with depot neuroleptics.

BACKGROUND: Stability of neuroleptic medication has been associated with optimal clinical effect and minimal side-effects. Depot administration is assumed to yield better stability. METHOD: Thirty patients on depot neuroleptic treatment were followed during three years with repeated measurements of plasma level and concurrent ratings of clinical symptoms and side-effects. RESULTS: Of 120 blood samples 35 (29%) measurements were outside +/-2 s.d. measurement error (expected 5%). Perphenazine levels were more variable (46%) than haloperidol (25%) and flupenthixol (12.5%). No relationship was found between side-effect ratings and fluctuations of plasma levels. CONCLUSION: Depot neuroleptic medication does not eliminate a clinically unwanted and sometimes marked variation in plasma level.

Adult↗
PubMed1995

Brain activation induced by the perceptual maze test: a PET study of cognitive performance.

We investigated with PET the cerebral activation pattern elicited by the perceptual maze test (PMT), a neuropsychological test used to evaluate organic brain injury. The PMT examines visuospatial skill, general intelligence, visually guided motor planning, and the ability to obey rules. Eight right-handed volunteers were examined with PET using the tracer [15O]butanol. Three paradigms containing the PMT, a motor control (SHAM), and a rest condition were examined twice in a randomized order. Solving the PMT caused extensive bilateral activations in the occipital lobe extending rostrally into the parietal lobe and caudally to the posterior part of the temporal lobe. Bilateral activations were also seen in the prefrontal, medial premotor, and the anterior cingulate cortex (ACC). The premotor and primary sensory motor cortices contralateral to the performing hand were also activated. Marked activations were noted in the visual system, including areas pertaining to visuospatial decoding. The previously defined functional network (ACC, prefrontal and posterior parietal cortex) for the maintenance of visuospatial attention was activated during the PMT. Extensive bilateral deactivations were seen in frontomedial, temporal, parietal, and posterior cingulate regions. This pattern may represent relatively decreased blood flow in cortical areas pertaining to sensory modalities that were not activated in the PMT. The decreased activity in these regions could also express diminished cognitive processing in neuronal systems that might interfere with the task-related performance.

Adult↗
PubMed1995

Smooth pursuit eye movements and neuropsychological impairments in schizophrenia.

Smooth pursuit eye movements (SPEM) and neuropsychological performance were examined in a sample of 29 drug-treated schizophrenic patients and 22 healthy controls. Patients had impairment in SPEM as well as in a wide range of neuropsychological tests (Wechsler Adult Intelligence Scale, Wisconsin Card Sorting Test. Finger Tapping, Reaction time, Selective attention, Trail-Making and Simultaneous Capacity). Performance indices were more affected than strategy-executive indices. Drug type (clozapine vs typical) and dose (chlorpromazine units) were not related to neuropsychological impairment among the patients. Indices from the whole range of tests accurately predicted a subjects' group identity (patient vs control). Impaired SPEM was predicted more accurately by tests assessing frontal functions. Seven patients, all men, had only marginal neuropsychological impairments.

Adult↗